LCM
NAMS icon

Legato Capital Management’s NewAmsterdam Pharma NAMS Stock Holding History

Legato Capital Management’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,570
Closed -$690K – 790
2026
Q1 		$690K Sell
21,570
-62,263
-74% -$2.03M 0.06% 416
2025
Q4 		$2.94M Buy
83,833
+60,463
+259% +$2.2M 0.25% 90
2025
Q3 		$665K Buy
23,370
+4,581
+24% +$110K 0.07% 400
2025
Q2 		$340K Buy
+18,789
New +$343K 0.04% 489

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Legato Capital Management's NAMS Position: Q2 2026 in Review

Legato Capital Management sold out of NewAmsterdam Pharma (NAMS) in Q2 2026, closing a stake of 21,570 shares — an estimated $690K sold.

Legato Capital Management first reported a position in NAMS in Q2 2025 and held it in 4 quarters. The position peaked at $2.94M in Q4 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Legato Capital Management reported no remaining NewAmsterdam Pharma position as of Q2 2026 after selling out during the quarter.
  • Legato Capital Management sold 21,570 NewAmsterdam Pharma shares in Q2 2026, an estimated $690K.
  • Legato Capital Management first reported a position in NewAmsterdam Pharma in Q2 2025 and held it in 4 quarters.
  • Legato Capital Management's NewAmsterdam Pharma position peaked at $2.94M in Q4 2025.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.